Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sipuleucel-T With or Without Continuing NHA in Metastatic Prostate Cancer
NCT05751941Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2023
- Primary completion
- Jul 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Moffitt Cancer Center. Started Feb 2023; status: active, not recruiting.
02
Drugs
sipuleucel-T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05751941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751941.